Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;13(5):e7075.
doi: 10.1002/cam4.7075.

Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Affiliations

Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Guihong Liu et al. Cancer Med. 2024 Mar.

Abstract

Purpose: A pathologic complete response (pCR) to neoadjuvant chemoradiotherapy (nCRT) is seen in up to 40% of the patients with esophageal squamous cell carcinoma (ESCC). No nomogram has been constructed for the prediction of pCR for patients whose primary chemotherapy was a taxane-based regimen. The aim is to identify characteristics associated with a pCR through analyzing multiple pre- and post-nCRT variables and to develop a nomogram for the prediction of pCR for these patients by integrating clinicopathological characteristics and hematological biomarkers.

Materials and methods: We analyzed 293 patients with ESCC who underwent nCRT followed by esophagectomy. Clinicopathological factors, hematological parameters before nCRT, and hematotoxicity during nCRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and evaluated for both discrimination and calibration.

Results: After surgery, 37.88% of the study patients achieved pCR. Six variables were included in the nomogram: sex, cN stage, chemotherapy regimen, duration of nCRT, pre-nCRT neutrophil-to-lymphocyte ratio (NLR), and pre-nCRT platelet-to-lymphocyte ratio (PLR). The nomogram indicated good accuracy and consistency in predicting pCR, with a C-index of 0.743 (95% confidence interval: 0.686, 0.800) and a p value of 0.600 (>0.05) in the Hosmer-Lemeshow goodness-of-fit test.

Conclusions: Female, earlier cN stage, duration of nCRT (< 62 days), chemotherapy regimen of taxane plus platinum, pre-nCRT NLR (≥2.199), and pre-nCRT PLR (≥99.302) were significantly associated with a higher pCR in ESCC patients whose primary chemotherapy was a taxane-based regimen for nCRT. A nomogram was developed and internally validated, showing good accuracy and consistency.

Keywords: esophageal squamous cell carcinoma; neoadjuvant chemoradiotherapy; nomogram; pathologic complete response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of included patients. ESCC, esophageal squamous cell carcinoma; nCRT, neoadjuvant chemoradiotherapy; pCR, pathologic complete response.
FIGURE 2
FIGURE 2
Nomogram for prediction of pCR after nCRT in patients with ESCC. For each patient, seven variables are assigned points on a nomogram, represented by seven lines moving upward. The sum of these points is then located on the “Total Points” axis. A line is drawn downward from this point to predict the probability of achieving pCR. ESCC, esophageal squamous cell carcinoma; pCR, pathologic complete response; PLR, platelet to lymphocyte ratio; nCRT, neoadjuvant chemoradiotherapy; NLR, neutrophil to lymphocyte ratio; TP, taxane and platinum agents.
FIGURE 3
FIGURE 3
Evaluation of the performance of the nomogram by discrimination and calibration. (A) ROC curve of the nomogram. (B) Calibration plots of the nomograms.

Similar articles

Cited by

References

    1. Shah MA, Altorki N, Patel P, Harrison S, Bass A, Abrams JA. Improving outcomes in patients with oesophageal cancer. Nat Rev Clin Oncol. 2023;20(6):390‐407. - PubMed
    1. Neoadjuvant Chemoradiotherapy followed by SurgeryVersus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open‐label clinical trial. J Clin Oncol. 2018;36(27):2796‐2803. - PMC - PubMed
    1. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative Chemoradiotherapy for esophageal or junctional. Cancer. 2012;366(22):2074‐2084. - PubMed
    1. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330‐4337. - PubMed
    1. Meguid RA, Hooker CM, Taylor JT, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138(6):1309‐1317. - PMC - PubMed

Publication types